Phase 4
Completed N=26
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
Alcohol Withdrawal
Source: ClinicalTrials.gov NCT01573052 ↗
Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Epworth Sleepiness Scale (ESS) — 6.35; 2.65 units on a scale
◆ Published Evidence
Established
46citations · ~4 / year
Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment.
Summary
A randomized, double-blind controlled trial comparing treatment outcomes between chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence, withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and alcohol craving.
Linked Publications
-
Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Epworth Sleepiness Scale (ESS) |
6.35; 2.65 | — |
| PRIMARY PENN Alcohol Craving Scale |
16.78; 10.74 | — |
| SECONDARY Clinical Institute Withdrawal Assessment-Alcohol (Revised)(CIWA-Ar) |
3.29; 4.33 | — |
Eligibility Criteria
Inclusion Criteria
- Alcohol dependent at risk for withdrawal symptoms
Exclusion Criteria
- Benzodiazepine dependent
Data sourced from ClinicalTrials.gov (NCT01573052) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.